[go: up one dir, main page]

BR0312778A - Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat - Google Patents

Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat

Info

Publication number
BR0312778A
BR0312778A BR0312778-8A BR0312778A BR0312778A BR 0312778 A BR0312778 A BR 0312778A BR 0312778 A BR0312778 A BR 0312778A BR 0312778 A BR0312778 A BR 0312778A
Authority
BR
Brazil
Prior art keywords
atherosclerosis
receptor antagonist
acat inhibitor
adp receptor
prevention
Prior art date
Application number
BR0312778-8A
Other languages
English (en)
Inventor
Fumitoshi Asai
Toshimori Inaba
Taketoshi Ogawa
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0312778A publication Critical patent/BR0312778A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA PREVENçãO OU TRATAMENTO DE ARTERIOSCLEROSE OU DOENçAS DERIVADAS DE ARTERIOSCLEROSE, E, USOS DE UM ANTAGONISTA DE RECEPTOR DE ADP E DE UM INIBIDOR DE ACAT". Uma composição medicinal caracterizada pelo fato de que um antagonista do receptor de ADP e um inibidor de ACAT são administrados, ou simultaneamente ou separadamente, em um intervalo definido. Uma composição medicinal, em que um antagonista do receptor de ADP e um inibidor de ACAT são administrados, ou simultaneamente ou separadamente, em um intervalo definido, e útil como um agente preventivo ou um remédio (em particular, um remédio) para arteriosclerose ou doenças derivadas de arteriosclerose, tais como doença cardíaca isquêmica, doença cerebral isquêmica e falha de circulação periférica em animais de sangue quente (em particular, humanos).
BR0312778-8A 2002-07-18 2003-07-17 Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat BR0312778A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002209165 2002-07-18
PCT/JP2003/009108 WO2004009119A1 (ja) 2002-07-18 2003-07-17 動脈硬化症治療のための医薬組成物

Publications (1)

Publication Number Publication Date
BR0312778A true BR0312778A (pt) 2005-05-03

Family

ID=30767676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312778-8A BR0312778A (pt) 2002-07-18 2003-07-17 Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat

Country Status (14)

Country Link
EP (1) EP1555032A1 (pt)
KR (1) KR20050025604A (pt)
CN (1) CN1681533A (pt)
AU (1) AU2003248077A1 (pt)
BR (1) BR0312778A (pt)
CA (1) CA2493384A1 (pt)
IL (1) IL166312A0 (pt)
MX (1) MXPA05000726A (pt)
NO (1) NO20050877L (pt)
PL (1) PL373383A1 (pt)
RU (1) RU2005104432A (pt)
TW (1) TW200407135A (pt)
WO (1) WO2004009119A1 (pt)
ZA (1) ZA200500431B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600497A (en) * 2001-02-02 2006-01-01 Sankyo Co Preparation of indoline derivative
MXPA05014086A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antiagregantes plaquetarios combinadas para su uso en el tratamiento y prevencion de eventos vasculares de origen isquemico.
KR101503083B1 (ko) * 2006-12-07 2015-03-16 다이이찌 산쿄 가부시키가이샤 고형 제제의 제조 방법
BRPI0719393B8 (pt) * 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
TWI488657B (zh) * 2006-12-07 2015-06-21 Daiichi Sankyo Co Ltd 貯藏安定性經改善之醫藥組成物及改善醫藥組成物之貯藏安定性的方法
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd PREPARATION WITH FILM COVER AND IMPROVED STABILITY
KR101442862B1 (ko) * 2006-12-07 2014-09-22 다이이찌 산쿄 가부시키가이샤 만니톨 또는 유당을 함유하는 고형 제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62167791A (ja) * 1986-01-20 1987-07-24 Morinaga Milk Ind Co Ltd 血小板凝集抑制剤
CN1042430C (zh) * 1993-02-10 1999-03-10 英国阿斯特拉药品有限公司 N－烷基－2－取代的atp类似物、其制备方法和用途
PT866059E (pt) * 1995-10-05 2002-03-28 Kyoto Pharma Ind Novos derivados heterociclicos e sua utilizacao medicina
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
WO2002004461A1 (en) * 2000-07-06 2002-01-17 Sankyo Company, Limited Hydropyridine derivative acid addition salts

Also Published As

Publication number Publication date
ZA200500431B (en) 2006-08-30
IL166312A0 (en) 2006-01-15
TW200407135A (en) 2004-05-16
KR20050025604A (ko) 2005-03-14
AU2003248077A1 (en) 2004-02-09
CN1681533A (zh) 2005-10-12
NO20050877L (no) 2005-02-18
RU2005104432A (ru) 2005-08-10
EP1555032A1 (en) 2005-07-20
MXPA05000726A (es) 2005-04-08
WO2004009119A1 (ja) 2004-01-29
PL373383A1 (en) 2005-08-22
CA2493384A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
BR0012450A (pt) Benzimidazóis substituìdos
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
UY26130A1 (es) Compuestos para tratar la obesidad
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
PT1140139E (pt) Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BRPI0412262A (pt) derivados de azepina como agentes farmacêuticos
DE69718734D1 (de) Bicyclische aromatische verbindungen
TR200101649T2 (tr) Piperazin türevleri.
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
PT1562954E (pt) Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a.
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
BR0016430A (pt) Método para o tratamento e/ou prevenção da tosse em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica
PT1124841E (pt) Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem
BR0312778A (pt) Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat
BR0207272A (pt) Método de tratamento de doenças ou condições de desmielinação
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]